Whether it’s a bull or bear market, TrendingWallStreet has you covered. Take a few minutes to register with us at http://www.trendingwallstreet.com/ to get exclusive access to our free stock reports.
Get more information on Twitter, Inc. and free access to the in-depth equity report at: www.TrendingWallStreet.com/stockquote/TWTR
Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA) made its impressive IPO debut in the market on Thursday. Dicerna opened at $30.00 even though its IPO was priced at $15.00. DRNA is a biopharmaceutical company focused on the discovery and development of innovative treatments for rare inherited diseases involving the liver and for cancers that are genetically defined. DRNA is using its RNA interference (RNAi) technology platform to build a broad pipeline in these therapeutic areas.
Get more information on Dicerna Pharmaceuticals, Inc. and free access to the in-depth equity report at: www.TrendingWallStreet.com/stockquote/DRNA
Get more information on Provectus Biopharmaceuticals, Inc. and free access to the in-depth equity report at: www.TrendingWallStreet.com/stockquote/PVCT
Geron Corporation (NASDAQ: GERN) shares closed up 23.56 percent with nearly 34 million shares traded. The stock had one of the biggest volume advances on the NASDAQ on Thursday. The company announced the pricing of its previously announced underwritten public offering of 22,500,000 shares of its common stock, offered at a price to the public of $4.00 per share. The gross proceeds to Geron from this underwritten public offering are expected to be approximately $90 million, before deducting the underwriting discount and other estimated offering expenses payable by Geron.
Get more information on Geron Corporation and free access to the in-depth equity report at: www.TrendingWallStreet.com/stockquote/GERN
Disclosure: TrendingWallStreet.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please read our report and visit our website, for complete risks and disclosures.